- Page 1 and 2: Do more, feel better, live longer T
- Page 3 and 4: The Annual Report was approved by t
- Page 5 and 6: Joint statement by the Chairman and
- Page 7 and 8: 04 GlaxoSmithKline Joint statement
- Page 9 and 10: Products - Pharmaceuticals Descript
- Page 11 and 12: Additionally, GlaxoSmithKline marke
- Page 13 and 14: Competition - Consumer Healthcare T
- Page 15 and 16: Operating activities Marketing and
- Page 17 and 18: Description of business GlaxoSmithK
- Page 19 and 20: Description of business GlaxoSmithK
- Page 21 and 22: Product approvals Country/Region Pr
- Page 23 and 24: As part of GlaxoSmithKline’s majo
- Page 25 and 26: Operating resources Intellectual pr
- Page 27 and 28: Compensation philosophy and program
- Page 29 and 30: Access to healthcare in the develop
- Page 31: GlaxoSmithKline gave unrestricted g
- Page 35 and 36: Corporate Executive Team (CET) JP G
- Page 37 and 38: The Annual General Meeting takes pl
- Page 39 and 40: Research and development Safety of
- Page 41 and 42: Remuneration report GlaxoSmithKline
- Page 43 and 44: The majority of the competitor pane
- Page 45 and 46: Performance graph 100 90 80 70 60 N
- Page 47 and 48: Non-Executive Directors Non-Executi
- Page 49 and 50: Non-Executive Directors’ share ar
- Page 51 and 52: Incentive plans Remuneration report
- Page 53 and 54: Operating and financial review and
- Page 55 and 56: 2002 Year World economy The world
- Page 57 and 58: Pharmaceutical sales by therapeutic
- Page 59 and 60: Consumer Healthcare sales 2002 2001
- Page 61 and 62: Earnings 2001 2002 (restated) CER%
- Page 63 and 64: Contractual obligations and commitm
- Page 65 and 66: Funding, maturity and counterparty
- Page 67 and 68: Stricter regulatory controls also h
- Page 69 and 70: Operating and financial review and
- Page 71 and 72: Latin America reported eight per ce
- Page 73 and 74: Selected financial data UK/US GAAP
- Page 75 and 76: Financial statements GlaxoSmithKlin
- Page 77 and 78: Independent Auditors’ report to t
- Page 79 and 80: Consolidated statement of profit an
- Page 81 and 82: Consolidated statement of cash flow
- Page 83 and 84:
Company balance sheet at 31st Decem
- Page 85 and 86:
2 Accounting policies Consolidation
- Page 87 and 88:
2 Accounting policies continued Sto
- Page 89 and 90:
6 Segment information continued Not
- Page 91 and 92:
7 Merger items, restructuring costs
- Page 93 and 94:
Notes to the financial statements G
- Page 95 and 96:
13 Earnings per share Notes to the
- Page 97 and 98:
Notes to the financial statements G
- Page 99 and 100:
19 Equity investments Notes to the
- Page 101 and 102:
Notes to the financial statements G
- Page 103 and 104:
Notes to the financial statements G
- Page 105 and 106:
30 Legal proceedings The Group is i
- Page 107 and 108:
30 Legal proceedings continued In F
- Page 109 and 110:
30 Legal proceedings continued In 2
- Page 111 and 112:
31 Acquisitions and disposals conti
- Page 113 and 114:
32 Financial instruments and relate
- Page 115 and 116:
32 Financial instruments and relate
- Page 117 and 118:
33 Employee costs continued Notes t
- Page 119 and 120:
33 Employee costs continued Notes t
- Page 121 and 122:
34 Employee share schemes continued
- Page 123 and 124:
34 Employee share schemes continued
- Page 125 and 126:
37 Reconciliation to US accounting
- Page 127 and 128:
37 Reconciliation to US accounting
- Page 129 and 130:
Notes to the financial statements G
- Page 131 and 132:
37 Reconciliation to US accounting
- Page 133 and 134:
37 Reconciliation to US accounting
- Page 135 and 136:
37 Reconciliation to US accounting
- Page 137 and 138:
37 Reconciliation to US accounting
- Page 139 and 140:
37 Reconciliation to US accounting
- Page 141 and 142:
38 Principal Group companies Notes
- Page 143 and 144:
38 Principal Group companies contin
- Page 145 and 146:
Financial record GlaxoSmithKline 14
- Page 147 and 148:
Financial record GlaxoSmithKline 14
- Page 149 and 150:
Financial record GlaxoSmithKline 14
- Page 151 and 152:
Financial record GlaxoSmithKline 14
- Page 153 and 154:
Investor information GlaxoSmithKlin
- Page 155 and 156:
Shareholder information Ordinary sh
- Page 157 and 158:
Share capital GlaxoSmithKline 155 A
- Page 159 and 160:
Cross reference to Form 20-F GlaxoS
- Page 161 and 162:
Index A Access to healthcare 27 Acc
- Page 163:
Contact details INTERNET Informatio